Showing up to 93 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.
NCT05785715: Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative ColitisPhase II Ulcerative Colitis trial by AbbVie. Stop reason: OPERATIONAL.
Sponsor Decision\_Not Safety Related
NCT04064827: A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)Phase III Chronic Kidney Disease (CKD) trial by AbbVie. Stop reason: OPERATIONAL.
Company Decision
NCT04189614: An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung CancerPhase I Cancer trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT04161885: A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)Phase III Acute Myeloid Leukemia (AML) trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT05941442: A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic DisorderPhase II Panic Disorder trial by AbbVie. Stop reason: OPERATIONAL.
Sponsor terminated due to significant enrollment and study design challenges
NCT04958031: A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related ApathyPhase II Apathy in Dementia trial by AbbVie. Stop reason: OPERATIONAL.
Sponsor Decision - Not Safety Related
NCT04686786: An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset SeizuresPhase II Seizures trial by AbbVie. Stop reason: EFFICACY/FUTILITY.
Closed early after CVL-865-SZ-001 (NCT04244175) did not meet its primary objective
NCT05028569: Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic MigrainePhase III Episodic Migraine trial by AbbVie. Stop reason: EFFICACY/FUTILITY.
The study was terminated early due to lack of efficacy from the primary analysis results.
NCT06579300: A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088Phase I Healthy Volunteer trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT06032546: A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382Phase II Human Immuno-deficiency Virus (HIV) Disease trial by AbbVie. Stop reason: OPERATIONAL.
Company Decision
NCT06158958: A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid TumorsPhase I Solid Tumors trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT05513703: A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Phase II Non Small Cell Lung Cancer trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT05368558: Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With SchizophreniaPhase III Schizophrenia trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT06618118: A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive DisorderPhase I Major Depressive Disorder (MDD) trial by AbbVie. Stop reason: OPERATIONAL.
Company Decision
NCT05316220: A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative ColitisPhase III Ulcerative Colitis (UC) trial by AbbVie. Stop reason: OTHER/UNKNOWN.
strategic considerations
NCT04948645: A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral SclerosisPhase I ALS trial by AbbVie. Stop reason: OPERATIONAL.
Company Decision
NCT04570631: Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple MyelomaPhase I Multiple Myeloma trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT06068868: Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Phase I Acute Myeloid Leukemia trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT04807972: Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer MetastasisPhase I Pancreatic Cancer trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT02470585: Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerPhase III Ovarian Cancer trial by AbbVie. Stop reason: OPERATIONAL.
Business decision not related to patient safety
NCT04972968: A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154Phase II Polymyalgia Rheumatica trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT04888585: Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)Phase II Rheumatoid Arthritis (RA) trial by AbbVie. Stop reason: OPERATIONAL.
Business decision
NCT05068284: A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's DiseasePhase II Crohn's Disease trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT06078202: A Study to Assess the Relative Bioavailability of Three Immediate-Release Tablet Formulations of ABBV-903 in Healthy Adult VolunteersPhase I Healthy Volunteers trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT06390722: A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic DermatitisPhase III Atopic Dermatitis trial by AbbVie. Stop reason: OPERATIONAL.
strategic decision
NCT04913610: Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus InfectionPhase II Onchocerciasis trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT04853368: Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic FibrosisPhase II Cystic Fibrosis (CF) trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT05956509: Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb SpasticityPhase I Upper Limb Spasticity trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT06093503: Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met ProteinPhase III Non-Small Cell Lung Cancer trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT06070948: A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female ParticipantsPhase I Healthy Volunteers trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT05606757: A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation TechniquePhase II Ventral Hernia trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT04912063: Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic SyndromePhase I Acute Myeloid Leukemia (AML) trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT04403763: Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With PresbyopiaPhase I Presbyopia trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT05044234: A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe PsoriasisPhase II Psoriasis trial by AbbVie. Stop reason: OPERATIONAL.
Company Decision
NCT06009237: A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese ParticipantsPhase I Healthy Volunteers trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT04480086: Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With MyelofibrosisPhase I Myelofibrosis (MF) trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT03859869: A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)Phase IV Exocrine Pancreatic Insufficiency (EPI) trial by AbbVie. Stop reason: OPERATIONAL.
Business Considerations (difficulty with enrollment)
NCT02203773: Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)Phase I Acute Myelogenous Leukemia trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT04895410: Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple MyelomaPhase I Multiple Myeloma trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT04804254: Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell CancersPhase I B-cell Lymphoma trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT03484520: A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaPhase I Cancer - Acute Myeloid Leukemia trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT05376839: A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic ImpairmentPhase I Hepatic Impairment trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT05475821: Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy ParticipantsPhase I Healthy Volunteers trial by AbbVie. Stop reason: OPERATIONAL.
Company decision: re-evaluation of risk vs benefit (based on animal data)
NCT03712787: An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)Phase II Alzheimer's Disease trial by AbbVie. Stop reason: EFFICACY/FUTILITY.
Discontinued because of lack of efficacy in the parent study (Study M15-566; NCT02880956).
NCT04272203: A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated CancersPhase I Acute Myeloid Leukemia (AML) trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT03148756: Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective EndocarditisPhase II Endocarditis trial by AbbVie. Stop reason: OPERATIONAL.
Study stopped due to business reasons.
NCT04965272: A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs AlonePhase II Generalized Anxiety Disorder trial by AbbVie. Stop reason: OPERATIONAL.
Strategic Decision
NCT03593213: Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With SchizophreniaPhase III Schizophrenia trial by AbbVie. Stop reason: OPERATIONAL.
FDA Released Allergan from this post marketing requirement
NCT02688790: Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial InfectionPhase I Bacterial Infections trial by AbbVie. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
NCT05217472: An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS)Phase II Sjogren's Syndrome (SS) trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Study canceled
NCT04127695: A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's DiseasePhase I Parkinson's Disease trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT03400306: A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian CancerPhase I Cancer - Ovarian trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT03797261: A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic MalignanciesPhase I Acute Myeloid Leukemia trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Safety
NCT04315311: Study Of Effects Of Oral CREON Capsules In Adult Participants With Exocrine Pancreatic Insufficiency Not Due To Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic CancerPhase IV Exocrine Pancreatic Insufficiency (EPI) trial by AbbVie. Stop reason: OPERATIONAL.
Business Decision
NCT03823378: A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With UpadacitinibPhase II Rheumatoid Arthritis (RA) trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Study M16-763 was terminated early as the benefit of each treatment arm from the feeder study (Study M16-063) did not provide appreciable evidence of differentiated clinical effect to warrant further long-term continuation.
NCT03033511: A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)Phase III Small Cell Lung Cancer trial by AbbVie. Stop reason: SAFETY.
Independent Data Monitoring Committee recommendation
NCT04178902: A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple MyelomaPhase I Multiple Myeloma (MM) trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT02573740: Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive ImpairmentPhase I Alzheimer's Disease trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Insufficient target engagement of ABT-957 (preclinical data)
NCT02220738: Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase InhibitorsPhase I Alzheimer's Disease trial by AbbVie. Stop reason: OPERATIONAL.
Slow subject enrollment
NCT03567616: A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple MyelomaPhase II Multiple Myeloma trial by AbbVie. Stop reason: SAFETY.
Following results of the primary progression-free survival analysis from Study NCT02755597, company-sponsored MM studies were placed on partial clinical hold (PCH). Sponsor did not pursue release of the PCH for this study.
NCT03419403: UNITE Study: Understanding New Interventions With GBM ThErapyPhase III Glioblastoma Multiforme trial by AbbVie. Stop reason: OTHER/UNKNOWN.
The study was terminated because clinical development of depatuxizumab mafodotin in glioblastoma was stopped due to lack of survival benefit.
NCT04666675: A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in BrazilPhase III Atopic Dermatitis (AD) trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT03360006: A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) CancerPhase I Acute Myeloid Leukemia (AML) trial by AbbVie. Stop reason: OPERATIONAL.
Strategic Reasons
NCT04274907: A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) ExpressionPhase I Non Small Cell Lung Cancer trial by AbbVie. Stop reason: OPERATIONAL.
Company Decision
NCT03368859: A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and BevacizumabPhase II Cancer trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Study may continue
NCT03391765: An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)Phase II Progressive Supranuclear Palsy (PSP) trial by AbbVie. Stop reason: EFFICACY/FUTILITY.
This study was prematurely discontinued because the program for progressive supranuclear palsy was discontinued due to lack of efficacy.
NCT02985879: A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)Phase II Progressive Supranuclear Palsy trial by AbbVie. Stop reason: EFFICACY/FUTILITY.
This study was prematurely discontinued because the program for progressive supranuclear palsy was discontinued due to lack of efficacy of study drug.
NCT03818542: A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell CarcinomaPhase I Head and Neck Cancer trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT04274933: A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor TherapyPhase I Breast Cancer trial by AbbVie. Stop reason: OPERATIONAL.
Company Decision
NCT02709889: Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid TumorsPhase I Malignant Melanoma trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT02412371: A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)Phase I Non-small Cell Lung Cancer Stage III trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Phase 2 was not conducted due to a change in the standard of care for newly diagnosed, unresectable Stage III NSCLC
NCT03026166: A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung CancerPhase I Small Cell Lung Cancer trial by AbbVie. Stop reason: OPERATIONAL.
Enrollment was stopped after the dose-limiting toxicity (DLT) evaluation phase of Cohort 2.
NCT02819999: A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung CancerPhase I Small Cell Lung Cancer trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT03035279: A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal CancerPhase I Colorectal Cancer trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT03343067: A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe PainPhase III Endometriosis trial by AbbVie. Stop reason: OPERATIONAL.
The study was terminated early for business reasons, not for safety concerns.
NCT03785184: A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose TherapyPhase II Multiple Myeloma trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT02897115: A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine TreatmentPhase IV Axial Spondyloarthritis trial by AbbVie. Stop reason: OPERATIONAL.
The study was terminated due to slow recruitment.
NCT03138408: SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial CancersPhase I Cancer trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT01858532: Study Of Diabetic Nephropathy With AtrasentanPhase III Diabetic Nephropathy trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT03334487: Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung CancerPhase III Small Cell Lung Cancer trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT03316794: A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)Phase I Breast Cancer trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Strategic considerations
NCT03145909: A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)Phase I Advanced Solid Tumors Cancer trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Safety
NCT02462525: Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple MyelomaPhase I Multiple Myeloma trial by AbbVie. Stop reason: OTHER/UNKNOWN.
No Go decision for ABBV-838
NCT01834638: Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)Phase II Schizophrenia trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Study endpoint in preceding base study M10-855 not met.
NCT03253185: A Study of SC-007 in Subjects With Advanced CancerPhase I Colorectal Cancer (CRC) trial by AbbVie. Stop reason: SAFETY.
Benefit/Risk Imbalance
NCT02365662: A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor ReceptorPhase I Head and Neck Squamous Cell Carcinoma trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Safety
NCT02504099: A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular CarcinomaPhase III Chronic Hepatitis C Infection trial by AbbVie. Stop reason: OPERATIONAL.
Study stopped due to low enrollment
NCT03145948: A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With PsoriasisPhase I Psoriasis trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Safety reason
NCT02951117: A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer TreatmentPhase I Multiple Myeloma trial by AbbVie. Stop reason: OPERATIONAL.
No participants enrolled
NCT02606630: [11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple SclerosisPhase I Multiple Sclerosis trial by AbbVie. Stop reason: OPERATIONAL.
Company decision
NCT02806362: Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)Phase III Chronic Hepatitis C Virus trial by AbbVie. Stop reason: OPERATIONAL.
Study halted prematurely, prior to enrollment of first participant
NCT02640833: A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K InhibitorPhase I Chronic Lymphocytic Leukemia trial by AbbVie. Stop reason: OTHER/UNKNOWN.
Study Stopped
NCT02429895: A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197Phase II Psoriatic Arthritis trial by AbbVie. Stop reason: OPERATIONAL.
Internal business decision